PRR7 antisense RNA 1 (PRR7-AS1)

PRR7 antisense RNA 1 (PRR7-AS1) is a long non-coding RNA that is overexpressed across multiple human cancers, particularly hepatocellular carcinoma and osteosarcoma, and is associated with poorer prognosis and more advanced disease stages. It does not code for a protein, but acts as a molecular regulator. PRR7-AS1 influences cancer cell proliferation and migration, likely through epigenetic mechanisms: it binds to RNF2, a Polycomb group protein, to promote histone H2A monoubiquitination and silence tumor suppressor genes such as MTUS1[5][6]. High PRR7-AS1 levels are also correlated with changes in immune cell infiltration and immune checkpoint gene expression, making it a potential biomarker for cancer prognosis and therapeutic response (notably, to immune checkpoint inhibitors)[2][4]. While not a classical drug target, it is of interest as a diagnostic and prognostic RNA biomarker, and as a putative modulator of oncogenic and immune regulatory pathways[2][4][5][6][7].

Other names

PRR7-AS1lncRNA PRR7-AS1long non-coding RNA PRR7-AS1

Not a direct drug target, but mechanistically involved in: - Binding to RNF2 (Ring finger protein 2), facilitating histone H2A lysine 119 monoubiquitination (H2AK119ub) and gene silencing (for example, of MTUS1 gene) - Acting as a competitive endogenous RNA (ceRNA) in cancer